Carl Zeiss Meditec AG reaffirmed earning guidance for 2022. The Company's outlook for fiscal year 2021/22 remains unchanged: Revenue is expected to grow at least to the same extent as the market.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
92.8 EUR | -1.85% | -5.16% | -6.16% |
May. 10 | CARL ZEISS MEDITEC AG : Hauck & Aufhauser gives a Buy rating | ZD |
May. 09 | CARL ZEISS MEDITEC AG : Deutsche Bank sticks Neutral | ZD |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.16% | 9.11B | |
+11.58% | 226B | |
+9.49% | 188B | |
+12.99% | 137B | |
+25.90% | 108B | |
+0.27% | 63.19B | |
+12.12% | 52.26B | |
+4.86% | 51B | |
+7.19% | 43.89B | |
+6.09% | 38.07B |
- Stock Market
- Equities
- AFX Stock
- News Carl Zeiss Meditec AG
- Carl Zeiss Meditec AG Reaffirms Earning Guidance for 2022